In the single-arm FULCRUM-VT trial, 59% of patients remained free of recurrent VT at 6 months, with less amiodarone use.
Mayo Clinic researchers report that a highly targeted, noninvasive form of radiation therapy reduced episodes of a ...
Adagio Medical Holdings, Inc. ADGM shares are up during Monday’s premarket session following the announcement of positive ...
Medical Device Network on MSN
Adagio Medical reports positive six-month results in FULCRUM-VT trial
The trial is evaluating the vCLAS cryoablation system at 20 centres across Canada and the US.
Abbott (NYSE:ABT) today shared new study findings supporting its pulsed field ablation (PFA) and conduction system pacing ...
Virtual replicas of individual patients’ hearts have allowed doctors to refine and personalize a lifesaving medical procedure for dangerous rhythm disturbances. Heart models may be just the leading ...
Working with "digital twins" of patients' hearts, doctors improved cardiac ablation outcomes for patients with life-threatening arrythmias. In the first clinical trials for cardiac digital twins ...
MINNEAPOLIS, March 25, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical study) ...
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac ...
SAN DIEGO--(BUSINESS WIRE)--Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced the publication of a peer-reviewed study in EP Europace evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results